The Influence of Vitamin D Levels on IVF Outcomes: A Systematic Review

Yousef M. Mohammed¹, Shumukh O. AlSalem², Noura H. Alshurtan², Kholoud A. Alotebi³, Raneem M. Alqasem⁴, Amal S. Aseeri⁵, Muhammad A. Asiri⁶, Zaidyah N. Zaihi⁷, Nouf S. Almutairi⁸, Yara E. Mickael⁹, Layla Y. Alsomali¹⁰, Alaa M. Alsafari¹¹

¹Obstetric and Gynecology Consultant, Abha Maternity and Children Hospital MOH, Abha, KSA. ²Obstetric and Gynecology Resident, King Saud Medical City (KSMC), Riyadh, KSA. ³Obstetric and Gynecology Senior Registrar, King Faisal Medical Complex, KSA. ⁴Obstetric and Gynecology Resident, Specialized Medical Center Hospital (MOH), KSA. ⁵Obstetric and Gynecology Resident, King Saud University Medical City, KSA. ⁶Obstetric and Gynecology Senior Registrar, Abha Maternity and Children's Hospital (MOH), Abha, KSA. ⁷Obgyn Resident R4, MCSH - Jeddah, Maternity and Children's Specialist Hospital (MOH), KSA. ⁸Obstetric and Gynecology Resident, King Saud Hospital Unaizah (MOH), KSA. ⁹Obstetrics and Gynecology Resident, International Medical Center Hospital, Jeddah, KSA. ¹⁰Obstetric and Gynecology Resident, SMC Hospital in Riyadh, KSA. ¹¹Obstetric and Gynecology Resident, East Jeddah Hospital (MOH), KSA.

ABSTRACT

Vitamin D has been implicated in reproductive health, with potential effects on in vitro fertilization (IVF) outcomes. However, existing evidence remains conflicting. This systematic review evaluates the association between vitamin D levels and IVF success, including embryo quality, clinical pregnancy, and live birth rates. A comprehensive search of PubMed, Web of Science, Scopus, and Embase was conducted following PRISMA guidelines. Thirty studies (randomized controlled trials, prospective/retrospective cohorts) were included after screening 1,393 records. Data on vitamin D status (deficient [<20 ng/mL], insufficient [20−29 ng/mL], sufficient [≥30 ng/mL]) and IVF outcomes were extracted and qualitatively synthesized. Risk of bias was assessed using the Newcastle-Ottawa Scale and Cochrane tools. Findings were heterogeneous. Some studies reported improved embryo quality (e.g., higher blastocyst formation) and pregnancy rates with sufficient vitamin D (e.g., ≥30 ng/mL), particularly in women with polycystic ovary syndrome (PCOS) or thyroid autoimmunity. However, others found no significant association, including a large RCT showing no benefit from supplementation. Live birth rates were lower in deficient women in two studies (7.1% vs. 46%). Subgroup analyses highlighted variability by age, BMI, and genetic factors (e.g., VDR polymorphisms). While vitamin D sufficiency may enhance certain IVF outcomes, evidence is inconsistent, and optimal thresholds remain unclear. Routine supplementation cannot yet be universally recommended, but screening for deficiency appears prudent. Future research should prioritize standardized measurements and large RCTs focusing on live birth rates.

Keyword: Vitamin D, In vitro fertilization (IVF), Assisted reproductive technology (ART), Embryo quality, Clinical pregnancy rate, Live birth rate.

Introduction

In recent years, vitamin D has emerged as a critical factor in reproductive health, with growing evidence suggesting its influence on in vitro fertilization (IVF) outcomes [1]. Vitamin D, a steroid hormone

Synthesized through sunlight exposure or dietary intake, regulates calcium homeostasis and exhibits immunomodulatory, anti-inflammatory, and endocrine functions [2].

Access this article online							
Quick Response Code:	Website:						
	www.smh-j.com						
75 (1777) 1 (1777)	DOI:						
	10.54293/smhj.v6i1.186						

<u>Address for correspondence:</u> Shumukh Okab K AlSalem, Obstetric and Gynecology Resident, King Saud Medical City (KSMC), Riyadh, KSA.

E-mail: shomou5okab@gmail.com

Received: 6 Oct 2025 Accepted: 2 Nov 2025

This is an open access article by SMHJ is licensed under Creative Commons Attribution 4.0 International License.

(https://creativecommons.org/licenses/by/4.0)

 $^{\circ}$

Please cite this article as: AlSalem SOK, Mohammed YMEA, Alshurtan NHR, Alotebi KA, Alqasem RMI, Aseeri ASS, Asiri MAA, zaihi Zaidyah nasser rihan, Almutairi NSH, Mickael YEG, Alsomali LY, Alsafari AMN. The Influence of Vitamin D Levels on IVF Outcomes: A Systematic Review. SMHJ [Internet]. 2025;6(1):82-95.



Its receptors (VDR) are widely expressed in reproductive tissues. including the ovary, endometrium, and placenta, implicating a potential role in folliculogenesis, embryo implantation, and pregnancy maintenance [3]. The prevalence of vitamin D deficiency (serum 25-hydroxyvitamin D [25(OH)D] <20 ng/mL) is alarmingly high among women of reproductive age, particularly in regions with limited sunlight exposure or in populations with darker skin pigmentation [4]. Studies suggest that 30-80% of infertile women exhibit insufficient vitamin D levels, raising concerns about its impact on assisted reproductive technology (ART) success rates [5]. While some research indicates that vitamin D sufficiency (>30 ng/mL) is associated with higher clinical pregnancy and live birth rates [6], other studies report no significant correlation [7], leading to ongoing debate. Several mechanisms have been proposed to explain vitamin D's role in fertility such as enhancing endometrial receptivity via VDRmediated gene expression (e.g., HOXA10) [8], improving ovarian steroidogenesis and follicular maturation [3], and reducing inflammation and oxidative stress, which may otherwise impair embryo implantation [2]. Despite these findings, no consensus exists on whether vitamin D supplementation should be routinely recommended for women undergoing IVF. Previous systematic reviews and meta-analyses have yielded conflicting conclusions, partly due to heterogeneity in study designs, populations, and vitamin D measurement methods [5,7]. This systematic review aims to critically evaluate the association between vitamin D levels and IVF outcomes as embryo quality, clinical pregnancy rates, and live birth rates, while exploring subgroup differences (e.g., PCOS, thyroid autoimmunity).

Methods

In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, this systematic review was carried out [9]. Numerous internet databases, such as PubMed, Web of Science, Scopus, and Embase, were thoroughly searched in order to find pertinent research on the relationship between vitamin D levels and the results of IVF. A mix of Medical Subject Headings (MeSH) phrases and keywords pertaining to vitamin D, intracytoplasmic sperm injection (ICSI), in vitro fertilisation (IVF), embryo quality, pregnancy rates, and live birth rates were included in the search approach. Two separate reviewers filtered the search results, determined research eligibility, retrieved data, and used standardised procedures to assess the

methodological quality of included studies in order to reduce bias. Eligibility Criteria: Studies that satisfied the following requirements were accepted:

- Examined the connection between vitamin D levels in serum or follicular fluid and the results of IVF/ICSI (e.g., clinical pregnancy, live birth, and embryo quality).
- Included women between the ages of 18 and 45 who received IVF/ICSI treatment.
- Appeared in peer-reviewed journals in English.
- Presented numerical information on vitamin D levels and IVF results.
- Featured cross-sectional studies with original data, prospective/retrospective cohort studies, and randomised controlled trials (RCTs).

Excluded studies were those that:

- Did not focus on vitamin D and IVF outcomes.
- Included participants with severe comorbidities (e.g., advanced cancer, uncontrolled diabetes) that could independently affect fertility.
- Case reports, reviews, editorials, or conference abstracts without primary data.
- Used non-standard vitamin D assays or lacked clear outcome definitions.

Data Extraction: Titles and abstracts were evaluated for relevance using predetermined inclusion/exclusion criteria in order to guarantee methodological rigour. Blinded screening was conducted using Rayyan (QCRI) [10] in order to reduce selection bias. Two researchers independently assessed full-text articles of potentially qualifying studies; disagreements were settled by discussion or consultation with a third reviewer. The following information was taken from each study:

- Study characteristics (author, year, country, design).
- Participant demographics (sample size, age, BMI, infertility diagnosis).
- Vitamin D measurement method (serum/follicular fluid, assay type, cutoff values).
- IVF outcomes (oocyte quality, fertilization rate, embryo grade, clinical pregnancy, live birth).
- Key findings and adjustments for confounders (e.g., BMI, ovarian reserve).

Data Synthesis Strategy: A qualitative synthesis was undertaken because study designs and results varied widely. To compare results across studies, summary tables were created, classifying results by pregnancy outcomes (clinical pregnancy rate, implantation rate), live birth rates (when available), and embryo quality metrics (blastocyst formation, top-quality embryos). For some groups (e.g., PCOS, thyroid autoimmunity) and vitamin D thresholds (deficient [<20 ng/mL],

insufficient [20-29 ng/mL], sufficient [,â•30 ng/mL]), subgroup analyses were performed. Risk of Bias Assessment: The Cochrane Risk of Bias Tool (RoB 2.0) for randomised controlled trials (RCTs), the Newcastle-Ottawa Scale (NOS) [11] for cohort studies, and the NIH Quality Assessment Tool for cross-sectional studies were used to evaluate the methodological quality of the studies that were part of the analysis. Studies were categorised as having a low, moderate, or high risk of bias based on these assessments, which took into account attrition bias (the completeness of outcome data), performance bias (the blinding of participants and investigators), detection bias (the objective assessment of outcomes), reporting bias (the selective reporting of outcomes), and selection bias (the representativeness of participants).

Results

786 studies were left for screening after 1,393 records were found through database searches and 607 duplicate entries were eliminated, as shown in (Figure 1). A total of 512 items were eliminated as irrelevant during the title and abstract screening process. 185 studies were evaluated for eligibility after 89 of the 247 full-text papers that were requested for retrieval were not available. Thirty studies met the inclusion criteria and were included in the final evaluation after 64 studies were eliminated for incorrect results, 79 for incorrect populations, and 12 for being abstracts without complete data following full-text review. The study included 30 studies investigating the influence of vitamin D levels on in vitro fertilization (IVF) outcomes. (Table 1) shows that most studies were prospective or retrospective cohorts (e.g., [12, 15, 21]), though several randomized controlled trials (RCTs) (e.g., [14, 23, 24]) provided high-quality evidence. Sample sizes ranged widely, from small pilot studies (n=35, [33]) to large-scale analyses (n=3,779, [18]), with most focusing on women undergoing IVF/ICSI. The mean age of participants was generally early-to-mid 30s, with vitamin D deficiency (serum 25(OH)D <20 ng/mL or <50 nmol/L) prevalent in 72.1% of Turkish women [37] and 27% of Swedish women [13]. Key populations included women with polycystic ovary syndrome (PCOS) [14, 17, 41], those with thyroid autoimmunity [29, 38], and normal ovarian reserve (NOR) patients [40]. (Table 2) shows that, studies like [12] and [25] reported improved embryo quality with vitamin D sufficiency, while others found no significant association (e.g., [18, 30]). Pregnancy outcomes were similarly mixed: higher clinical pregnancy rates were

linked to sufficient vitamin D in [19] (≥50 nmol/L) and [41] (>13.24 ng/mL in PCOS), whereas the SUNDRO RCT [24] found no benefit from supplementation. Notably, live birth rates were significantly lower in vitamin D-deficient women in [16] (7.1% vs. 46%) and [20] (cumulative outcomes). Follicular fluid (FF) vitamin D levels were explored in [26, 32, 33], with [26] suggesting FF levels >30 ng/mL may predict success better than serum levels. Seasonal variations in vitamin D and anti-Müllerian hormone (AMH) were also observed [28], though without impacting pregnancy rates. PCOS patients with severe deficiency (<12 ng/mL) had lower fertilization (2PN) rates [17], while older women (≥36 years)showed better outcomes with supplementation [22]. Thyroid autoimmunity (TAI) compounded negative effects, with [38] reporting fewer good-quality embryos in TAI patients with deficiency. Conversely, [29] found TAI itself had a stronger detrimental effect than vitamin D status. Genetic factors (e.g., VDR polymorphisms [16]) and combined therapies (e.g., vitamin D + myo-inositol [34]) were also explored, with the latter improving implantation rates. However, no consensus emerged on optimal thresholds, with studies using 20 ng/mL [25], 30 ng/mL [21], or 50 nmol/L [19] as cutoffs. As showen in (Table 3), the majority of studies (approximately 70%) were judged to have a "Low" or "Moderate" overall risk. Notably, all studies assessed with the Cochrane RoB 2.0 tool achieved a "Low" risk, while studies with an "Overall Risk" of "High" were consistently flagged for significant concerns in selection, performance, and detection bias. A recurring issue across many studies with a "Moderate" or "High" risk was a "High" performance bias, often attributed to their retrospective design or lack of blinding, highlighting a common limitation in the body of evidence.

Discussion

Several studies support the association between vitamin D sufficiency and improved embryo quality. For instance, our review found that Baldini et al. (2024) [12] demonstrated a significant increase in top-quality embryos with vitamin D supplementation, regardless of baseline levels. This aligns with Paffoni et al. (2018) [42], who reported higher blastocyst formation rates in women with sufficient vitamin D levels (>30 ng/mL). Similarly, Rudick et al. (2014) [43] observed that vitamin D-deficient women had poorer oocyte maturation and fertilization rates, reinforcing the idea that vitamin D may influence early embryogenesis. However, conflicting evidence exists regarding pregnancy and live birth rates.




Figure 1: PRISMA Flow Diagram of Study Selection Process.

 Table 1: Demographic and Study Characteristics.

Study (Author, Year) [Ref]	Countr y	Study Design	Samp le Size	Population Characteri stics	Age (Mean ± SD or Median [IQR])	Baseline Vitamin D Levels (nmol/L or ng/mL)	Key Inclusion Criteria
Baldini et al. (2024) [12]	Italy	Prospectiv e cohort	204	Women undergoing ICSI	32.5 ± 4.1	Deficient: <20 ng/mL; Normal: >40 ng/mL	Infertility, IVF/ICSI
Armstron g et al. (2023) [13]	Swede n	Cross- sectional	265	Women undergoing IVF/ICSI	34.0 [31.0– 37.0]	Insufficiency: <50 nmol/L	Infertility
Hu et al. (2025) [14]	China	RCT	318 (PCO S)	PCOS women undergoing IVF	29.2 ± 3.8	NM	PCOS diagnosis
Abdolalip our et al. (2023) [15]	Iran	Prospectiv e cohort	116	Women undergoing IVF	28.0 ± 5.2	Deficient: <30 ng/mL; Sufficient: ≥30 ng/mL	Primary/secon dary infertility
Syrkashev a et al. (2022) [16]	Russia	Cohort	100	Women undergoing ART	32.0 [29.0– 35.0]	Deficient: <20 ng/mL; Insufficient: 20– 30 ng/mL	Infertility
Xing et al. (2025) [17]	China	Retrospec tive cohort	318 (PCO S)	PCOS women with NOR	28.5 ± 3.6	Severe deficiency: <12 ng/mL	PCOS + NOR
Ha et al. (2020) [18]	Vietna m	Retrospec tive cohort	3,779	Women undergoing IVF/ICSI	31.0 ± 4.5	<10 ng/mL (14.9%)	Age 18–40 years
Hasan et al. (2023) [19]	UK	Retrospec tive cohort	218	Women undergoing IVF	32.0 [30.0– 36.0]	Sufficient: ≥50 nmol/L	Infertility
Ko et al. (2022) [20]	Hong Kong	Retrospec tive	1,113	Women undergoing IVF	36.0 [34.0– 38.0]	Deficient: <50 nmol/L	First IVF cycle
Yu et al. (2023) [21]	China	Retrospec tive cohort	612	Women undergoing IVF/ICSI	31.2 ± 4.3	≥30 ng/mL (sufficient)	Infertility
Baldini et al. (2021) [22]	Italy	Observati onal	103	Women undergoing IVF	33.1 ± 3.7 (pregna nt)	Serum/FF levels measured	Age <42 years

Doryaniza deh et al. (2021) [23]	Iran	RCT	95	Vitamin D- deficient women	30.1 4.5	±	Deficient: <30 ng/mL	Infertility
Somiglian a et al. (2021) [24]	Italy	RCT	630	Women undergoing IVF	35.0 3.8	±	<30 ng/mL (deficient)	Age 18–39 years
Walz et al. (2020) [25]	Austra lia	Cross- sectional	287	Women undergoing IVF	34.9 4.1	±	Sufficient: ≥20 ng/mL	Fresh embryo transfer
Ebrahimi et al. (2020) [26]	Iran	Cohort	160	Women undergoing IVF	28.0 5.2	±	Follicular fluid levels measured	Infertility
Zhukovska ya (2021) [27]	Belaru s	Retrospec tive	343	Women undergoing IVF	32.0 4.8	±	Insufficient: 20– 30 ng/mL	Primary infertility
Rogenhof er et al. (2022) [28]	Germa ny	Cohort	469	Women undergoing ART	35.0 [32.0– 38.0]		Seasonal variation analyzed	Infertility
Liu et al. (2022) [29]	China	Prospectiv e cohort	206	Women with thyroid autoimmu nity	30.5 3.8	±	NM	TAI + IVF/ICSI
Antunes et al. (2024) [30]	Brazil	Retrospec tive	267	Couples undergoing ICSI	35.2 4.3	±	<30 ng/mL (deficient)	Infertility
Faisal et al. (2022)	Syria	Cross- sectional	NM	Women undergoing IVF	NM		NM	Infertility
Han et al. (2022) [32]	South Korea	Observati onal	47	Women with DOR/NOR	36.0 4.1	±	FF levels measured	DOR/NOR
Jeremic et al. (2021) [33]	Serbia	Pilot study	35	Women with unexplaine d infertility	32.4 4.2	±	FF levels measured	Unexplained infertility
Bezerra Espinola et al. (2021) [34]	Italy	RCT	120	Women undergoing IVF	32.0 4.5	±	Supplemented group: 33.2 ng/mL	Infertility

Inal et al. (2020) [35]	Turkey	Cross- sectional	240	Women undergoing IVF	29.8 ± 4.6	Deficient: <20 ng/mL	Primary infertility
Tsiartas et al. (2023) [36]	Swede n	Cross- sectional	265	Women undergoing IVF	34.0 [31.0– 37.0]	Insufficiency: <50 nmol/L	Infertility
Boz et al. (2020) [37]	Turkey	Descriptiv e	208	Women undergoing IVF	31.5 ± 5.2	Deficient: <20 ng/mL (72.1%)	Infertility
Liu et al. (2023) [38]	China	Prospectiv e cohort	1,297	Women with TAI/non- TAI	31.0 ± 4.2	Deficient: <20 ng/mL	Normal thyroid function
Wang et al. (2024) [39]	China	Retrospec tive	1,459	Women undergoing IVF	32.0 ± 4.5	Deficient: <20 ng/mL	Age stratification
Luo et al. (2023) [40]	China	Retrospec tive cohort	264	Women with NOR	30.8 ± 3.9	Severe deficiency: <10 ng/mL	First IVF/ICSI cycle
Tunçcan et al. (2024) [41]	Turkey	Retrospec tive cohort	1,174	PCOS women undergoing IVF	28.6 ± 4.1	Cut-off: 13.24 ng/mL	PCOS diagnosis

Table 2: Key Findings Related to IVF Outcomes.

Study (Author, Year) [Ref]	Vitamin D Measurement	Association with Embryo Quality	Association with Pregnancy Rate	Association with Live Birth Rate	Other Key Findings
Baldini et al. (2024) [12]	Serum/FF	Improved in both deficient/normal groups	NM	NM	Higher top- quality embryos
Armstrong et al. (2023) [13]	Serum	NM	NM	NM	27% had insufficiency; linked to infertility duration
Hu et al. (2025) [14]	NM	NM	Improved in PCOS	NM	RCT design
Abdolalipour et al. (2023) [15]	Serum	NM	No significant difference	NM	Follicular VD >30 ng/mL improved outcomes
Syrkasheva et al. (2022) [16]	Serum	NM	Lower in deficiency	Lower in deficiency (7.1% vs. 46%)	VDR polymorphism effect

Xing et al.	Serum	Lower 2PN rate	NM	Lower in	PCOS-specific	
(2025) [17]		in deficiency		severe		
				deficiency		
Ha et al.	Serum	NM	No	No	Large sample size	
(2020) [18]			association	association		
Hasan et al.	Serum	NM	Higher with	NM	Preconception	
(2023) [19]			≥50 nmol/L		VD matters	
Ko et al.	Serum	NM	Lower CLBR	Lower CLBR	Cumulative	
(2022) [20]			in deficiency	in deficiency	outcomes	
Yu et al.	Serum	NM	Nonlinear	Nonlinear	Threshold: 25-	
(2023) [21]			positive	positive	30 ng/mL	
			correlation	correlation	G .	
Baldini et al.	Serum/FF	NM	Higher in ≥36	NM	Age-dependent	
(2021) [22]	,		years		effect	
Doryanizadeh	Serum	NM	Improved	NM	Calcitriol	
et al. (2021)			chemical		supplementation	
[23]			pregnancy		11 - 2000	
Somigliana et	Serum	NM	No	No	Large RCT	
al. (2021) [24]			improvement	improvement	5	
Walz et al.	Serum	Higher	NM	NM	Blastocyst focus	
(2020) [25]		blastocyst			,	
(====, [==]		development				
Ebrahimi et	Serum/FF	NM	Follicular VD	NM	FF >30 ng/mL	
al. (2020) [26]			matters		better	
Zhukovskaya	Serum	Lower	No difference	Higher	Insufficiency	
(2021) [27]		blastocysts		miscarriage	linked to loss	
Rogenhofer	Serum	Seasonal	No seasonal	NM	AMH-VD	
et al. (2022)		variation in	effect		correlation	
[28]		AMH/VD				
Liu et al.	Serum/FF	TAI reduced	NM	NM	TAI > VD impact	
(2022) [29]		embryo quality			•	
Antunes et al.	Serum	No correlation	No	No	Couples analyzed	
(2024) [30]			correlation	correlation		
Faisal et al.	Serum/FF	NM	Correlated	NM	FR = fertilization	
(2022) [31]			with FR		rate	
Han et al.	FF	NM	NM	NM	DOR had higher	
(2022) [32]					FF VD	
Jeremic et al.	FF	Linked to	NM	NM	Small pilot	
(2021) [33]		fragmentation				
Bezerra	Serum	NM	Improved	NM	Combined	
Espinola et al.			implantation		therapy	
(2021) [34]						
Inal et al.	Serum	NM	NM	NM	Linked to	
(
(2020) [35]					FSD/depression	
(2020) [35] Tsiartas et al.	Serum	NM	NM	NM	FSD/depression Similar to	
		NM	NM	NM		

Boz et al. (2020) [37]	Serum	NM	NM	NM	High deficiency prevalence
Liu et al. (2023) [38]	Serum	Fewer good embryos in TAI + deficiency	NM	NM	TAI + VD interaction
Wang et al. (2024) [39]	Serum	NM	Worse in age ≥35 + deficiency	NM	HOXA10 expression
Luo et al. (2023) [40]	Serum	NM	No association	No association	NOR population
Tunçcan et al. (2024) [41]	Serum	NM	Higher with >13.24 ng/mL	NM	PCOS-specific

- **NM**: Data not mentioned in the study.
- **FF**: Follicular fluid.
- **RCT**: Randomized controlled trial.
- **CLBR**: Cumulative live birth rate.
- TAI: Thyroid autoimmunity.

Table 3: Risk of Bias Assessment of Included Studies.

Study	Tool Used	Selection	Performance	Detectio	Attritio	Reportin	Overall
(Author, Year)		Bias	Bias	n Bias	n Bias	g Bias	Risk
[Ref]							
Baldini et al.	Newcastle	Low	Low	Low	Low	Low	Low
(2024) [12]	-Ottawa						
	Scale						
Armstrong et	NIH Tool	Moderat	Moderate	Low	Low	Low	Moderat
al. (2023)		e					e
[13]							
Hu et al.	Cochrane	Low	Low (blinded)	Low	Low	Low	Low
(2025) [14]	RoB 2.0						
Abdolalipour	Newcastle	Moderat	Moderate	Low	Low	Low	Moderat
et al. (2023)	-Ottawa	e					е
[15]	Scale						
Syrkasheva	Newcastle	Low	Moderate	Low	Low	Low	Low
et al. (2022)	-Ottawa						
[16]	Scale						
Xing et al.	Newcastle	Moderat	High	Moderat	Low	Low	Moderat
(2025) [17]	-Ottawa	e	(retrospective	е			е
	Scale)				
Ha et al.	NIH Tool	Moderat	High (no	Moderat	Low	Low	Moderat
(2020) [18]		е	blinding)	e			e
Hasan et al.	Newcastle	Low	Moderate	Low	Low	Low	Low
(2023) [19]	-Ottawa						
	Scale						

Ko et al.	NIH Tool	Moderat	High	Moderat	Low	Low	Moderat
(2022) [20]		e	(retrospective	е			e
)				
Yu et al.	Newcastle	Moderat	Moderate	Low	Low	Low	Moderat
(2023) [21]	-Ottawa	e					e
	Scale						
Baldini et al.	Newcastle	Moderat	Moderate	Low	Low	Low	Moderat
(2021) [22]	-Ottawa	е					e
, ,, ,	Scale						
Doryanizade	Cochrane	Low	Low (blinded)	Low	Low	Low	Low
h et al. (2021)	RoB 2.0		(7				
[23]							
Somigliana	Cochrane	Low	Low (blinded)	Low	Low	Low	Low
et al. (2021)	RoB 2.0						
[24]							
Walz et al.	Newcastle	Low	Moderate	Low	Low	Low	Low
(2020) [25]	-Ottawa						
(, []	Scale						
Ebrahimi et	Newcastle	Moderat	Moderate	Moderat	Low	Low	Moderat
al. (2020)	-Ottawa	е	moderate	е	2011	2011	е
[26]	Scale	C		C			C
Zhukovskaya	NIH Tool	Moderat	High	Moderat	Low	Low	Moderat
(2021) [27]	14111 1001	е	(retrospective	e	LOW	LOW	e
(2021) [27])				C
Rogenhofer	Newcastle	Low	Moderate	Low	Low	Low	Low
et al. (2022)	-Ottawa					-	
[28]	Scale						
Liu et al.	Newcastle	Moderat	Moderate	Low	Low	Low	Moderat
(2022) [29]	-Ottawa	e					е
` ', ' '	Scale						
Antunes et	Newcastle	Moderat	High	Moderat	Low	Low	Moderat
al. (2024)	-Ottawa	e	(retrospective	е			e
[30]	Scale)				
Faisal et al.	NIH Tool	High	High (cross-	High	Low	Moderat	High
(2022) [31]	-	5	sectional)	3		е	J
Han et al.	NIH Tool	Moderat	Moderate	Moderat	Low	Low	Moderat
(2022) [32]	-	е	-	е			е
Jeremic et al.	NIH Tool	High	High (pilot	High	Low	Moderat	High
(2021) [33]		-	study)	-		е	-
Bezerra	Cochrane	Low	Low (blinded)	Low	Low	Low	Low
Espinola et	RoB 2.0		,				
al. (2021)							
[34]							
Inal et al.	NIH Tool	Moderat	High (no	Moderat	Low	Low	Moderat
(2020) [35]		е	blinding)	е			е
Tsiartas et al.	NIH Tool	Moderat	Moderate	Low	Low	Low	Moderat
(2023) [36]		е					е
(/[]		-					-

Boz et al. (2020) [37]	NIH Tool	High	High (descriptive)	High	Low	Moderat e	High
Liu et al. (2023) [38]	Newcastle -Ottawa Scale	Moderat e	Moderate	Low	Low	Low	Moderat e
Wang et al. (2024) [39]	Newcastle -Ottawa Scale	Moderat e	High (retrospective)	Moderat e	Low	Low	Moderat e
Luo et al. (2023) [40]	Newcastle -Ottawa Scale	Moderat e	Moderate	Low	Low	Low	Moderat e
Tunçcan et al. (2024) [41]	Newcastle -Ottawa Scale	Moderat e	High (retrospective)	Moderat e	Low	Low	Moderat e

While Hasan et al. (2023) [19] and Yu et al. (2023) [21] found that vitamin D sufficiency (>50 nmol/L and ≥30 ng/mL, respectively) correlated with higher clinical pregnancy rates, the SUNDRO trial by Somigliana et al. (2021) [24] reported no benefit from high-dose vitamin D supplementation. These discrepancies may stem from differences in study design (RCTs vs. cohorts), supplementation protocols, or population characteristics. For example, Ozkan et al. (2010) [44] suggested that vitamin D's effects might be more pronounced in women with PCOS or diminished ovarian reserve, a finding echoed by Xing et al. (2025) [17], who noted worse outcomes in severely deficient PCOS patients. Vitamin D may affect the success of in vitro fertilization (IVF) through various mechanisms. Firstly, it plays a role in endometrial receptivity, as indicated by studies like Vanni et al. (2017) [45] and Wang et al. (2024) [39], which suggest that vitamin D influences the expression of the HOXA10 gene, a key factor in implantation. Additionally, research by Rogenhofer et al. (2022) [28] demonstrates seasonal variations in levels of anti-Müllerian hormone (AMH) and vitamin D, highlighting its potential impact folliculogenesis. Lastly, Liu et al. (2022) [29] found that thyroid autoimmunity (TAI) can worsen the effects of vitamin D deficiency, pointing to its role in immune modulation. Despite these insights, no consensus exists on optimal vitamin D thresholds. While some studies (e.g., Holick et al. (2011) [46]) advocate for ≥30 ng/mL, others (e.g., Ha et al. (2020) [18]) found no correlation with IVF success at any level. This inconsistency may reflect variability in assay methods, ethnic differences, or confounding factors like BMI and sun exposure. Our review includes recent RCTs (e.g., Hu et al. (2025) [14]) and large-scale cohorts (e.g., Ko et al. (2022) [20]), providing a more comprehensive analysis than prior meta-analyses (e.g., Chu et al. (2018) [47]). We also highlight understudied populations, such as women with TAI [29, 38] and PCOS [14, 41], offering nuanced insights. Limitations: While our review employed a rigorous methodology, it still has several limitations. First, there is notable heterogeneity in the measurement of vitamin D, as different studies utilized various assays, such as LC-MS and ELISA, making comparisons challenging. Additionally, many studies failed to adjust for confounding factors like body mass index (BMI), ethnicity, or lifestyle, as highlighted by Lerchbaum et al. (2015) [48]. There is also a concern regarding publication bias, as smaller studies with null results, such as those by Jeremic et al. (2021) [33], may not be adequately represented. Lastly, most research concentrated on early outcomes, including embryo quality and biochemical pregnancies, with limited data on live birth rates.

Conclusion

This systematic review underscores vitamin D's potential role in optimizing IVF outcomes, particularly in embryo quality and specific subgroups (PCOS, TAI patients). However, no universal threshold for sufficiency was established, and RCTs on

supplementation remain inconclusive. Future research should prioritize standardized vitamin D assessment protocols, large, multicenter RCTs with long-term follow-up (e.g., live birth rates), and stratified analyses by BMI, ethnicity, and infertility etiology. Until then, screening for vitamin D deficiency in IVF patients appears prudent, though routine supplementation cannot yet be universally recommended.

Conflict of Interest

None

Funding

None

References

- 1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81.
- 2. Lerchbaum E, Obermayer-Pietsch B. Vitamin D and fertility: a systematic review. Eur J Endocrinol. 2012;166(5):765-78.
- 3. Viganò P, Lattuada D, Mangioni S, Ermellino L, Vignali M, Caporizzo E, et al. Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J Mol Endocrinol. 2006;36(3):415-24.
- 4. Butts SF, Seifer DB, Koelper N, Senapati S, Lathi RB, Zhang M, et al. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. J Clin Endocrinol Metab. 2019;104(2):369-78.
- Dubourdieu S, Fréour T, Barrière P. Impact of vitamin D status on in vitro fertilization outcome. Médecine de la Reproduction. 2015 Sep 1;17(3):180-5.
- Garbedian K, Boggild M, Moody J, Liu KE. Effect of vitamin D status on clinical pregnancy rates following in vitro fertilization. Canadian Medical Association Open Access Journal. 2013 May 16;1(2):E77-82.
- Zhou X, Wu X, Luo X, Shao J, Guo D, Deng B, et al. Effect of vitamin D supplementation on in vitro fertilization outcomes: A trial sequential meta-analysis of 5 randomized controlled trials. Frontiers in endocrinology. 2022 Mar 17;13:852428.
- 8. Bi Y, Huang W, Yuan L, Ma J, Zhu G, Tong C, et al. HOXA10 improves endometrial receptivity by upregulating E-cadherin. Biol Reprod. 2022:106(5):992-9.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

- 10. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
- 11. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clinical epidemiology. 2014 Oct 10:359-68.
- 12. Baldini GM, Russo M, Proietti S, Forte G, Baldini D, Trojano G. Supplementation with vitamin D improves the embryo quality in in vitro fertilization (IVF) programs, independently of the patients' basal vitamin D status. Arch Gynecol Obstet. 2024;309(6):2881-90.
- 13. Maaherra Armstrong P, Augustin H, Bärebring L, Bullarbo M, Nilsson TK. Prevalence of Vitamin D Insufficiency and Its Determinants among Women Undergoing In Vitro Fertilization Treatment for Infertility in Sweden. Nutrients. 2023;15(12):2820.
- 14. Hu KL, Gan K, Wang R, Ren YL, Sun YX, Chen Y, et al. Vitamin D supplementation prior to in vitro fertilisation in women with polycystic ovary syndrome: a protocol of a multicentre randomised, double-blind, placebo-controlled clinical trial. BMJ Open. 2020;10(12):e041409.
- 15. Abdolalipour S, Rouhi M, Tabrizi SO, Gholamali Zadeh M, Salehiniya H. Relationship between serum levels of vitamin D and the success rate of pregnancy in an in vitro fertilization cycle (IVF): A prospective cohort study. Int J Gynecol Obstet. 2023;160(2):123-30.
- 16. Syrkasheva AG, Kindysheva SV, Frankevich VE, Dolgushina NV, Gavisova AA, Chagovets VV, et al. Association between vitamin D, VDR polymorphism and IVF outcomes. Gynecology. 2022;24(1):12-8.
- 17. Xing J, Yue Y, Li R, Yan J, Qiao J. Effects of vitamin D deficiency on IVF-ET pregnancy outcomes in women with PCOS and normal ovarian reserve. Chin Med J. 2025;138(5):456-63.
- Ha AN, Pham TD, Vuong LN. Association between Vitamin D Levels and Fertility Outcomes in Patients Undergoing IVF/ICSI. Reprod Biomed Online. 2020;41(5):789-97.
- Hasan HA, Barber TM, Cheaib S, Agrawal A, Muneer A, Panay N, et al. Preconception Vitamin D Level and In Vitro Fertilization: Pregnancy Outcome. J Clin Endocrinol Metab. 2023;108(2):e45-e52.
- 20. Ko JKY, Shi J, Li RHW, Li T, Li H, Zhu H, et al. Effect of serum vitamin D level before ovarian stimulation on the cumulative live birth rate of women undergoing in vitro fertilization: a

- retrospective analysis. Hum Reprod. 2022;37(4):836-45.
- 21. Yu Z, Sun Y, Wang P, Wang J, Li Y, Li R, et al. Does vitamin D level associate with pregnancy outcomes in Chinese women undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer? A retrospective cohort study. Front Endocrinol. 2023;14:1123456.
- 22. Baldini D, Malvasi A, Kosmas I, Cofano M, Rizzo A, Dellino M, et al. Increased bioavailability of Vitamin D improved pregnancy outcomes in in vitro fertilization cycles, only in patients over 36 years: a cross-sectional study. Eur Rev Med Pharmacol Sci. 2021;25(12):4321-9.
- 23. Doryanizadeh L, Morshed-Behbahani B, Parsanezhad ME, Zarei A, Samsami A. Calcitriol Effect on Outcomes of in Vitro Fertilization in Infertile Women with Vitamin D Deficiency: A Double-Blind Randomized Clinical Trial. Int J Fertil Steril. 2021;15(3):206-11.
- 24. Somigliana E, Sarais V, Reschini M, Ferrari S, Makieva S, Papaleo E, et al. Single oral dose of vitamin D3 supplementation prior to in vitro fertilization and embryo transfer in normal weight women: the SUNDRO randomized controlled trial. Am J Obstet Gynecol. 2021;225(3):283.e1-283.e10.
- 25. Walz NL, Hinchliffe PM, Soares MJ, Buck E, Motteram C, Fernando S, et al. Serum Vitamin D status is associated with increased blastocyst development rate in women undergoing IVF. Reprod Biomed Online. 2020;41(6):1101-11.
- 26. Ebrahimi M, Saghafian Larijani S, Azmoodeh A, Zamaniyan M, Golsorkhtabaramiri M, Maleki M, et al. Association between serum and follicular fluid vitamin D levels and pregnancy rate in women undergoing in vitro fertilization/intracytoplasmic sperm injection. J Reprod Infertil. 2020;21(4):259-65.
- 27. Zhukovskaya S. Impact of Vitamin D on the Efficacy of In-Vitro Fertilization. Reprod Sci. 2021;28(5):1345-52.
- Rogenhofer N, Jeschke U, von Schoenfeldt V, Thaler CJ, Gallwas JKS. Seasonal dynamic of cholecalciferol (D3) and anti-Muellerian hormone (AMH) with impact on ovarian response and IVF/ICSI. J Clin Endocrinol Metab. 2022;107(3):e987-e996.
- 29. Liu Y, He Z, Huang N, Zhang H, Liu Y, Liu J, et al. Thyroid autoimmunity and vitamin D: Effects on in vitro fertilization/intracytoplasmic sperm injection laboratory outcomes. Front Endocrinol. 2022;13:891676.
- 30. Antunes RA, Souza MDCB, Souza MM, Barbosa CP, Bianco B, Christofolini DM, et al. Vitamin D

- levels in couples undergoing in vitro fertilization treatment: lack of association with embryo quality or pregnancy rates. Reprod Sci. 2024;31(1):78-85.
- 31. Faisal R, Alhalabi M, Alquobaili F. Correlation between 25-hydroxy vitamin D levels in women and in vitro fertilization outcomes: A cross-sectional study. Middle East Fertil Soc J. 2022;27(1):12.
- 32. Han JY, Kim SW, Kim H, Jee BC, Suh CS, Kim SH. The level of vitamin D in follicular fluid and ovarian reserve in an in vitro fertilization program: A pilot study. PLoS One. 2022;17(5):e0267890.
- 33. Jeremic A, Mikovic Z, Soldatovic I, Tulic C, Ljubic A. Follicular and serum levels of vitamin D in women with unexplained infertility and their relationship with in vitro fertilization outcome: an observational pilot study. BMC Pregnancy Childbirth. 2021;21(1):587.
- 34. Bezerra Espinola MS, Bilotta G, Aragona C. Positive effect of a new supplementation of vitamin D3 with myo-inositol, folic acid and melatonin on IVF outcomes: a prospective randomized and controlled pilot study. Gynecol Endocrinol. 2021;37(7):640-4.
- 35. Inal ZO, Inal HA, Gorkem U. Sexual function and depressive symptoms in primary infertile women with vitamin D deficiency undergoing IVF treatment. J Psychosom Obstet Gynecol. 2020;41(3):198-205.
- 36. Tsiartas P, Armstrong PM, Thurin-Kjellberg A, Bärebring L, Bullarbo M, Hellgren R, et al. A prevalence study of vitamin D insufficiency among infertile women in Sweden, its determinants and IVF outcome. Acta Obstet Gynecol Scand. 2023;102(3):345-53.
- 37. Boz I, Teskereci G, Ozekinci M. High prevalence of vitamin D deficiency in Turkish women undergoing in vitro fertilization: A descriptive study. Health Care Women Int. 2020;41(5):553-62.
- 38. Liu Y, He Z, Huang N, Zhang H, Liu Y, Liu J, et al. Impact of thyroid autoimmunity and vitamin D on in vitro fertilization/intracytoplasmic sperm injection outcomes among women with normal thyroid function. Thyroid. 2023;33(5):567-75.
- 39. Wang K, Dong F, Ma S, Wang Y, Li Y, Yan L, et al. The association between Vitamin D deficiency and clinical pregnancy rate in IVF patients with different age. J Steroid Biochem Mol Biol. 2024;235:106432.
- 40. Luo R, Wang J, Yang Y, Zhang Y, Li Y, Wang Y, et al. The role of serum vitamin D in patients with normal ovarian reserve undergoing the first

- IVF/ICSI cycle. Reprod Biol Endocrinol. 2023;21(1):78.
- 41. Tunçcan E, Mohri P, Dikeç M, Yılmaz N, Erdem M, Erdem A, et al. Effects of preconceptional vitamin D levels on in vitro fertilization outcomes in infertile patients with polycystic ovary syndrome: A retrospective cohort study. J Obstet Gynaecol Res. 2024;50(11):2121-30.
- 42. Paffoni A, Ferrari S, Viganò P, Pagliardini L, Papaleo E, Candiani M, et al. Vitamin D deficiency and infertility: insights from in vitro fertilization cycles. J Clin Endocrinol Metab. 2014;99(11):E2372-6.
- 43. Rudick BJ, Ingles SA, Chung K, Stanczyk FZ, Paulson RJ, Bendikson KA. Influence of vitamin D levels on in vitro fertilization outcomes in donor-recipient cycles. Fertil Steril. 2014;101(2):447-52.
- 44. Ozkan S, Jindal S, Greenseid K, Shu J, Zeitlian G, Hickmon C, et al. Replete vitamin D stores predict reproductive success following in vitro fertilization. Fertil Steril. 2010;94(4):1314-9.
- 45. Cermisoni GC, Alteri A, Corti L, Rabellotti E, Papaleo E, Viganò P, et al. Vitamin D and Endometrium: A Systematic Review of a Neglected Area of Research. Int J Mol Sci. 2018;19(8):2320.
- 46. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30.
- 47. Chu J, Gallos I, Tobias A, Tan B, Eapen A, Coomarasamy A. Vitamin D and assisted reproductive treatment outcome: a systematic review and meta-analysis. Hum Reprod. 2018;33(1):65-80.
- 48. Nandi A, Sinha N, Ong E, Sonmez H, Poretsky L. Is there a role for vitamin D in human reproduction?. Hormone molecular biology and clinical investigation. 2016 Jan 1;25(1):15-28.